利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

587 条记录 (耗时 0.043 秒)

    Use of Fungicides for the Treatment of Fish Mycoses
    61.
    发明申请
    Use of Fungicides for the Treatment of Fish Mycoses 审中-公开
    使用杀真菌剂治疗鱼类真菌病

    公开(公告)号：US20120071531A1

    公开(公告)日：2012-03-22

    申请号：US13302946

    申请日：2011-11-22

    申请人： Isolde Häuser-Hahn ,  Klaus Stenzel ,  Ulrike Wachendorff-Neumann

    发明人： Isolde Häuser-Hahn ,  Klaus Stenzel ,  Ulrike Wachendorff-Neumann

    IPC分类号： A61K31/4152 ,  A61P31/10 ,  A61K31/415 ,  C07D233/86 ,  C07D233/90

    CPC分类号： A61K31/539 ,  A61K31/4166

    摘要： Process for the protection of fish and invertebrates and all their stages of development against or for the treatment of mycoses caused by fungi of the genera Saprolegnia, Aphanomyces, Achlyaflagellata and other species important in aquacultures by use of 2-[[[[1-[3-(1-fluoro-2-phenylethyl)oxy]phenyl]ethylidene]amino]oxy]methyl]alpha-(methoxyimino)-N-methyl-alphaE-benzeneacetamide, amisulbrom, cyazofamid, enestrobin, famoxadone, fenamidone, fluoxastrobin, orysastrobin, picoxystrobin and pyribencarb. This use leads to an inhibition or destruction of pathogenic fungi.The composition, comprising at least one fungicide selected from the abovementioned group for use in fish farming and keeping is suitable for the prophylaxis and therapy of diseases of fish in aquaculture, in breeding ponds, breeding tanks, aquariums, natural stretches of game fish waters, ponds, and marine fish farms. Addition to the water and feed and direct application are the associated use forms. The addition of the composition according to the invention to the water decreases fungal infections of spawn and fish.

    摘要翻译： 保护鱼类和无脊椎动物及其所有发展阶段的方法，针对或治疗由Sap藜属，Aphanomyces，Achlyaflagellata和其他在水产养殖中重要的物种引起的真菌病，通过使用2 - [[[[1- [ 3-（1-氟-2-苯基乙基）氧基]苯基]亚乙基]氨基]氧基]甲基]-α-（甲氧基亚氨基）-N-甲基-α-苯乙酰胺，异山梨醇，环唑酰胺，烯雌胺，恶唑酮，芬那敏，氟西汀， ，吡肟菌素和pyribencarb。 这种用途导致致病真菌的抑制或破坏。 包含至少一种选自上述用于养殖和保存的组的杀真菌剂的组合物适用于预防和治疗水产养殖中的鱼类，育种池，养殖池，水族箱，游戏鱼水的天然延伸， 池塘和海洋养殖场。 添加水和饲料和直接应用是相关的使用形式。 将根据本发明的组合物加入水中会降低产卵和鱼类的真菌感染。

    METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS
    64.
    发明申请
    METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS 审中-公开
    TRAIL-DEATH受体激动剂/激活剂的方法和组合

    公开(公告)号：US20110172234A1

    公开(公告)日：2011-07-14

    申请号：US13073665

    申请日：2011-03-28

    申请人： Rakesh Srivastava ,  Sharmila Shankar ,  Alexander D. MacKerell, JR.

    发明人： Rakesh Srivastava ,  Sharmila Shankar ,  Alexander D. MacKerell, JR.

    IPC分类号： A61K31/5377 ,  C12N5/00 ,  A61K31/5025 ,  A61K31/497 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/44 ,  A61K31/37 ,  A61K31/4192 ,  A61K31/433 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/194 ,  A61K31/522 ,  A61K31/421 ,  A61K31/137 ,  A61P35/00

    CPC分类号： A61K31/41 ,  A61K31/192

    摘要： This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.

    摘要翻译： 本发明描述了一系列用于预防和治疗诸如癌症的疾病的方法和组合物。 本发明的一个方面描述了可以用于结合死亡受体TRAIL-R1 / DR4和/或TRAIL-R2 / DR5的小分子基药物，并在保护正常细胞的同时诱导癌细胞凋亡。 本发明还描述了TRAIL死亡受体激动剂/激活剂（DRA）及其用途，例如通过胱天蛋白酶-8诱导凋亡和胱天蛋白酶-3激活。 本发明还描述了使用DRAs作为单药治疗或治疗癌症的方法，例如乳腺癌，前列腺癌，结肠癌，胰腺癌，卵巢癌，肺癌和脑癌，白血病，淋巴瘤，多发性骨髓瘤和间皮瘤。 结合其他疗法。

    Pyrazolone Derivative
    67.
    发明申请
    Pyrazolone Derivative 审中-公开
    吡唑啉酮衍生物

    公开(公告)号：US20100324091A1

    公开(公告)日：2010-12-23

    申请号：US12666015

    申请日：2008-06-23

    申请人： Noriaki Gomi ,  Shinji Ina ,  Kenjirou Yamana ,  Yoshio Kaneko

    发明人： Noriaki Gomi ,  Shinji Ina ,  Kenjirou Yamana ,  Yoshio Kaneko

    IPC分类号： A61K31/454 ,  C07D231/20 ,  A61K31/4152 ,  C07D401/06 ,  A61P7/02

    CPC分类号： C07D231/20 ,  C07D231/22 ,  C07D401/06 ,  C07D405/12

    摘要： A pyrazolone derivative represented by formula (I) below: wherein R1 to R3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a fibrolytic activity, and is effective for preventing and/or treating tissue fibrotic diseases (lung fibrosis, kidney fibrosis, etc.) and diseases of which a pathological thrombus becomes the cause, such as ischemic cardiac diseases (cardiac infarction and angina pectoris), atrial thrombus, lung embolism, deep thrombophlebitis, disseminated intravascular clotting, ischemic brain diseases (brain infarction, brain hemorrhage), and arterial sclerosis. In addition, a pharmaceutical agent for preventing and/or treating the disease conditions or the symptoms mediated by plasminogen activator inhibitor-1, comprising the novel pyrazolone derivative according to the present invention is also provided.

    摘要翻译： 由下式（I）表示的吡唑啉酮衍生物：其中R1至R3与权利要求中所定义相同; 或光学异构体，其药学上可接受的盐，或其水合物或溶剂化物。 根据本发明的新型吡唑啉酮衍生物具有PAI-1产生抑制活性，组织纤维化抑制活性和纤维分解活性，对预防和/或治疗组织纤维化疾病（肺纤维化，肾纤维化等）有效 ）和病理性血栓成为原因的疾病，如缺血性心脏病（心肌梗死和心绞痛），心房血栓，肺栓塞，深部血栓性静脉炎，弥漫性血管内凝血，缺血性脑病（脑梗死，脑出血）等） 动脉硬化。 此外，还提供了包含根据本发明的新型吡唑啉酮衍生物的用于预防和/或治疗疾病状况或由纤溶酶原激活物抑制剂-1介导的症状的药剂。